Molecular Formula | C17H14Cl2F2N4OS |
Molar Mass | 431.29 |
Density | 1.54±0.1 g/cm3(Predicted) |
Solubility | DMSO :34 mg/mL (78.83 mM) |
Appearance | White powder. |
pKa | 9.51±0.50(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
In vitro study | BMS-5 (LIMKi 3) inhibits cofilin-Ser3 phosphorylation in a dose-dependent manner in Nf2 ΔEx2 mouse Schwann cells (MSCs) with an IC 50 of ~2 µM. BMS-5 (LIMKi 3) reduces Nf2 ΔEx2 MSC viability in a dose-dependent manner with an IC 50 of 3.9 µM, but does not significantly reduce the viability of control Nf2 flox2/flox2 MSCs at equivalent BMS-5 concentrations. At 10 µM BMS-5, Nf2 ΔEx2 MSC viability is 40% compared to 83% for controls. |
In vivo study | BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01). |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.319 ml | 11.593 ml | 23.186 ml |
5 mM | 0.464 ml | 2.319 ml | 4.637 ml |
10 mM | 0.232 ml | 1.159 ml | 2.319 ml |
5 mM | 0.046 ml | 0.232 ml | 0.464 ml |
biological activity | BMS-5 (LIMKi 3) is a potent inhibitor of LIM kinases (LIMK), the IC50 values for LIMK1 and LIMK2 were 7 nM and 8 nM, respectively. |
Target | Value |
LIMK1 (Cell-free assay) | 7 nM |
LIMK2 (Cell-free assay) | 8 nM |